ALX Oncology Holdings narrows 2025 net loss to $101.7M
ALX Oncology Holdings (NASDAQ:ALXO) reported fourth-quarter and full-year 2025 results on Friday, highlighting a fundamental shift toward a biomarker-driven strategy that could redefine patient selection for its immuno-oncology pipeline.










